Study to Evaluate the Pharmacokinetics of Firsocostat or Fenofibrate in Adults With Normal and Impaired Hepatic Function
Status:
Completed
Trial end date:
2019-05-13
Target enrollment:
Participant gender:
Summary
The primary objectives of this study are to evaluate the single-dose pharmacokinetics (PK) of
firsocostat in adults with normal hepatic function, and mild, moderate, or severe hepatic
impairment and to evaluate the single-dose PK of fenofibrate in adults with normal hepatic
function and mild hepatic impairment.